Kwang Dong Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Kwang Dong Pharmaceutical has a total shareholder equity of ₩616.7B and total debt of ₩285.3B, which brings its debt-to-equity ratio to 46.3%. Its total assets and total liabilities are ₩1,182.2B and ₩565.6B respectively. Kwang Dong Pharmaceutical's EBIT is ₩26.7B making its interest coverage ratio 14.1. It has cash and short-term investments of ₩218.3B.
Key information
46.3%
Debt to equity ratio
₩285.31b
Debt
| Interest coverage ratio | 14.1x |
| Cash | ₩218.26b |
| Equity | ₩616.67b |
| Total liabilities | ₩565.58b |
| Total assets | ₩1.18t |
Recent financial health updates
Is Kwang Dong Pharmaceutical (KRX:009290) Using Too Much Debt?
Apr 29
Kwang Dong Pharmaceutical (KRX:009290) Seems To Use Debt Quite Sensibly
Jan 19Recent updates
Kwang Dong Pharmaceutical's (KRX:009290) Weak Earnings May Only Reveal A Part Of The Whole Picture
Nov 24There Is A Reason Kwang Dong Pharmaceutical Co., Ltd.'s (KRX:009290) Price Is Undemanding
Aug 06Kwang Dong Pharmaceutical's (KRX:009290) Solid Profits Have Weak Fundamentals
Mar 25Kwang Dong Pharmaceutical Co., Ltd.'s (KRX:009290) Price Is Right But Growth Is Lacking
Mar 20Is Kwang Dong Pharmaceutical (KRX:009290) Using Too Much Debt?
Apr 29Is Now The Time To Put Kwang Dong Pharmaceutical (KRX:009290) On Your Watchlist?
Apr 06Did Business Growth Power Kwang Dong Pharmaceutical's (KRX:009290) Share Price Gain of 117%?
Mar 18Is Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Popular Amongst Insiders?
Mar 01Should Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Be Part Of Your Dividend Portfolio?
Feb 14Estimating The Fair Value Of Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290)
Feb 01Kwang Dong Pharmaceutical (KRX:009290) Seems To Use Debt Quite Sensibly
Jan 19If You Like EPS Growth Then Check Out Kwang Dong Pharmaceutical (KRX:009290) Before It's Too Late
Jan 06Here's What We Like About Kwang Dong Pharmaceutical's (KRX:009290) Upcoming Dividend
Dec 24
Can You Imagine How Kwang Dong Pharmaceutical's (KRX:009290) Shareholders Feel About The 54% Share Price Increase?
Dec 18Is There More To The Story Than Kwang Dong Pharmaceutical's (KRX:009290) Earnings Growth?
Dec 04What Type Of Shareholders Own The Most Number of Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Shares?
Nov 21Financial Position Analysis
Short Term Liabilities: A009290's short term assets (₩718.4B) exceed its short term liabilities (₩510.5B).
Long Term Liabilities: A009290's short term assets (₩718.4B) exceed its long term liabilities (₩55.1B).
Debt to Equity History and Analysis
Debt Level: A009290's net debt to equity ratio (10.9%) is considered satisfactory.
Reducing Debt: A009290's debt to equity ratio has increased from 24.6% to 46.3% over the past 5 years.
Debt Coverage: A009290's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: A009290's interest payments on its debt are well covered by EBIT (14.1x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 12:14 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kwang Dong Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tae Gi Ha | SK Securities Co., Ltd. |
| Jayaprabha Dhavale | Virtua Research Inc. |